Latest Articles

Publication Date
All News Scientific
Endometriosis framework launched 18 months late but promises major improvements in women’s care - Irish Examiner

Endometriosis framework launched 18 months late but promises major improvements in women’s care Irish Examiner

Published: Oct. 18, 2025, 3 p.m.
Read Full Article
Minister for Health publishes new endometriosis framework - RTE.ie

Minister for Health publishes new endometriosis framework RTE.ie

Published: Oct. 18, 2025, 2:26 p.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - Lelezard

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer Lelezard

Published: Oct. 18, 2025, 12:47 p.m.
Read Full Article
Shrutika Arjun shares her surgery journey and recovery after endometriosis treatment: I'm advised to take a 45-day break - Hindustan Times

Shrutika Arjun shares her surgery journey and recovery after endometriosis treatment: I'm advised to take a 45-day break Hindustan Times

Published: Oct. 18, 2025, 12:37 p.m.
Read Full Article
Shrutika Arjun shares her surgery journey and recovery after endometriosis treatment: I'm advised to take a 45-day break | Hindustan Times - Hindustan Times

Shrutika Arjun shares her surgery journey and recovery after endometriosis treatment: I'm advised to take a 45-day break | Hindustan Times Hindustan Times

Published: Oct. 18, 2025, 12:37 p.m.
Read Full Article
Dylan Sprouse reveals wife Barbara Palvin walked 2025 Victoria’s Secret Fashion Show on broken foot months after endometriosis surgery - AOL.com

Dylan Sprouse reveals wife Barbara Palvin walked 2025 Victoria’s Secret Fashion Show on broken foot months after endometriosis surgery AOL.com

Published: Oct. 18, 2025, 11:13 a.m.
Read Full Article
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen The AI Journal

Published: Oct. 18, 2025, 10:28 a.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - The AI Journal

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer The AI Journal

Published: Oct. 18, 2025, 10:20 a.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - GlobeNewswire

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer GlobeNewswire

Published: Oct. 18, 2025, 10 a.m.
Read Full Article
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen Business Wire

Published: Oct. 18, 2025, 10 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!